- alphalex™ peptide-drug conjugates (PDCs) demonstrate tumor-selective delivery and potent anticancer activity
- Preclinical data show robust efficacy as monotherapy and in combination with standard-of-care treatments
- Findings potentially position alphalex PDCs in patients who have progressed following TOP1-based antibody-drug conjugates
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) — Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics, today announced new preclinical data from its alphalex™ technology, which were presented at the ESMO Targeted Anticancer Therapies (TAT) Congress 2025 being held March 3-5 in Paris, France. The findings demonstrate that Cybrexa’s antigen-agnostic PDC platform selectively delivers highly potent microtubule inhibitors to tumor cells, suppressing tumor growth while inducing a durable anti-tumor immune response.
Unlike antibody-drug conjugates (ADCs), alphalex PDCs use a pH-driven targeting approach to enable broad tumor applicability and avoid the toxicities often associated with antigen-based drug targeting. By exploiting tumor acidity, the alphalex platform ensures precise intracellular drug delivery to potentially reduce off-target effects while enhancing therapeutic impact.
Preclinical Findings at ESMO TAT 2025
The poster, “Characterization of Antigen-Agnostic Tumor-Selective Delivery and Immunomodulatory Activities of Auristatin and Maytansinoid alphalex™ Peptide-Drug Conjugates,” highlighted preclinical results evaluating the efficacy, safety, and immune-modulating effects of alphalex conjugates across mouse and rat xenograft and syngeneic models, including colorectal, melanoma, renal, and …
